LEGISLATIVE BUDGET BOARD Austin, Texas FISCAL NOTE, 89TH LEGISLATIVE REGULAR SESSION March 28, 2025 TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: SB493 by Kolkhorst (Relating to certain protected disclosures or communications by pharmacists and pharmacies regarding prescription drug benefits.), Committee Report 1st House, Substituted No significant fiscal implication to the State is anticipated. It is assumed that any costs associated with the bill could be absorbed using existing resources. Local Government ImpactNo significant fiscal implication to units of local government is anticipated. Source Agencies: b > td > 515 Board of Pharmacy LBB Staff: b > td > JMc, NPe, GDZ, DPE
LEGISLATIVE BUDGET BOARD
Austin, Texas
FISCAL NOTE, 89TH LEGISLATIVE REGULAR SESSION
March 28, 2025
TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: SB493 by Kolkhorst (Relating to certain protected disclosures or communications by pharmacists and pharmacies regarding prescription drug benefits.), Committee Report 1st House, Substituted
TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services
FROM: Jerry McGinty, Director, Legislative Budget Board
IN RE: SB493 by Kolkhorst (Relating to certain protected disclosures or communications by pharmacists and pharmacies regarding prescription drug benefits.), Committee Report 1st House, Substituted
Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services
Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services
Jerry McGinty, Director, Legislative Budget Board
Jerry McGinty, Director, Legislative Budget Board
SB493 by Kolkhorst (Relating to certain protected disclosures or communications by pharmacists and pharmacies regarding prescription drug benefits.), Committee Report 1st House, Substituted
SB493 by Kolkhorst (Relating to certain protected disclosures or communications by pharmacists and pharmacies regarding prescription drug benefits.), Committee Report 1st House, Substituted
No significant fiscal implication to the State is anticipated.
No significant fiscal implication to the State is anticipated.
It is assumed that any costs associated with the bill could be absorbed using existing resources.
Local Government Impact
No significant fiscal implication to units of local government is anticipated.
Source Agencies: b > td > 515 Board of Pharmacy
515 Board of Pharmacy
LBB Staff: b > td > JMc, NPe, GDZ, DPE
JMc, NPe, GDZ, DPE